STOCKS TELEGRAPH

Tag: ANCN

  • Here is why the Anchiano Therapeutics Ltd. (ANCN) stock has soared

    Here is why the Anchiano Therapeutics Ltd. (ANCN) stock has soared

    Anchiano Therapeutics Ltd. (NASDAQ: ANCN) stock soared by 5.37% to the current price of $4.71.

    ANCN has finally merged with Chemomab Ltd.

    The reason for this price increase can correlate with the much-anticipated news of the delayed merger between the two Israeli-based companies. The merger took place on the 15th of March, as was announced by Anchiano Therapeutics Ltd. (ANCN) by sending invitation letters to shareholders about the special meeting to approve the merger.

    Why ANCN stock news did not fare well in the past

    Anchiano Therapeutics Ltd (ANCN) has been developing major news in the past, but the report did not sustain its hype and kept dying out. One of the reasons is because the merger was expected to proceed earlier into the year 2021, and before the merger, the biotech company released news about initial trials of cancer research which were then discontinued in the second phase. The reason so is because the data analysis of treatment through gene therapy suggested that the treatment of bladder cancer had very little probability of complete responses in the patients

    What’s the next plan of action after the merger?

    Now that the merger has taken place, the 16-year old company, AnchianoTherapeutics Ltd (ANCN), will switch its trade ticker to “CMMB” and its public company name to Chemomab Therapeutics Ltd. After this merger, Chemomab Ltd would become the majority holder of the merged company. They will focus on the PIPE financing to advance CM-101 into Phase 2 clinical trials in rare fibrotic indications.

    The news that indicates to support this financing is that the merged companies have also announced a private investment of $45.5 million. This personal investment is a combination of original and new investors who now see hope in the ANCN’s positive stock movement.

    When we look at the details of the financing, it indicates the sale of 41,908,232 ADSs. The warrants that accompany these shares are more than 4 million (4,190,819 to be precise). The penny-stock price at which they were sold is $1.08433 per share, which is also the warrant’s exercise price. One thing to note here is that the pre-reverse split will take effect immediately before the merger’s closing.

    Why are CM 101 phase-2 trials significant?

    Furthermore, the merged-company can now focus on the trial inceptions for CM 101. CM 101 phase 2 trials will focus on orphan indications of inflammatory-fibrotic diseases. This is significant for investors from the point-of-view of being that the specific diseases targeted in this trial are sclerosing cholangitis (PSC) and systemic sclerosis both damage multiple organs, and both have unmet needs with the patients suffering from debilitating pain due to no FDA-approved diseases.

     Positive news of the success of the phase2 trial can lead to the possibility of FDA approval, which will correspond to a substantial uplift in the stock-movement of the then-merged Chemomab Therapeutics Ltd.

  • Early Morning Vibes: 4 Top Trending Stocks To Watch Right Now

    Early Morning Vibes: 4 Top Trending Stocks To Watch Right Now

    On March 5, the American stock exchanges closed in the green zone. The S&P 500 rose 1.95% to 3842 points, the Dow Jones added 1.85%, the NASDAQ rose 1.55%. All sectors, led by the energy sector, showed a confident growth, which continues to rally supported by oil prices. After the OPEC + decision to leave the production level unchanged, the energy quotes are moving up. Treasury yields were held near weekly highs. The Fed has confirmed its long-term plans to maintain the current parameters of monetary policy.

    Company News

    Online real estate marketplace CoStar Group (CSGP: + 5.3%) abandoned the acquisition of CoreLogic (CLGX) due to the impact of rising rates on the prospects for the mortgage refinancing market.

    Apparel retailer Gap (GPS: + 7.6%) posted a decline in revenue, but EPS was above forecast. The prospects for the development of the Old Navy and Athleta brands are noted.

    Insurance company Guidewire Software (GWRE: -4.8%) did better than expected, but margins are worrisome.

    Today, global stock markets are showing mixed dynamics. On Saturday, the Senate passed a $ 1.9 trillion stimulus package. It includes a reduction in weekly unemployment benefits from $ 400 to $ 300, direct payments of $ 1,400 for about 85% of American families, $ 350 billion in state and local government assistance, as well as funding a vaccination campaign and expanding tax credits for children. On March 9, a vote on the package will be held in the House of Representatives, after which the law will be submitted to the President for signature. Market participants are confident that the law will be adopted in the first half of March.

    The labor market statistics released on Friday pleasantly surprised investors. The unemployment rate fell to 6.2%, and the leisure and hospitality industry became a driver of new job growth. Against the background of a decrease in the incidence of COVID-19 and active vaccination, some states have eased quarantine restrictions: the mandatory wearing of masks and the observance of social distance in public places have been canceled. This revitalized tourism and recreation, but heightened the risk of the spread of the coronavirus. To date, about 17% of the US population has received the vaccine, and this is not enough to stop the epidemic.

    Uncertain appetite for risk. The 10-year Treasury rate hovers around the 1.55% mark. Brent oil futures rise to $ 70. Gold dropped to $ 1698.

    Technically, the S&P 500 marked a short-term downtrend, maintaining medium-term positive momentum. The broad market index found support near 3700, below the long-term uptrend. In the medium term, mixed dynamics is expected with the nearest support zone of 3640-3700 points.

    Today Top Movers


    Net Element Inc. (NASDAQ: NETE) shares are trading up 22.27% at $10.87 at the time of writing. Mullen Technologies, Inc. which previously announced a definitive agreement to merge with Net Element in a stock-for-stock reverse merger in which Mullen’s stock holders will receive a majority of the outstanding stock in the post-merger company, revealed today a strategic partnership with NexTech Batteries Inc. as an EV battery supplier and key partner for battery development and technologies.

    Anchiano Therapeutics Ltd. (ANCN) stock soared 109.58% to $7.0 in the pre-market trading. 

    Adaptive Biotechnologies Corporation (ADPT), a Biotechnology company, rose about 11.3% at $47.0 in pre-market trading Monday. The company recently declared that the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for T-Detect™ COVID to confirm recent or prior COVID-19 infection. 

    XpresSpa Group Inc. (XSPA) grew over 26.54% at $2.05 in pre-market trading today. On March 4, 2002, the XpresSpa Group,Inc. (Nasdaq: XSPA) announced it has signed a contract with the Port of Seattle for a COVID-19 popup testing facility at at Seattle-Tacoma International Airport (SEA).

    Top Upgrades & Downgrades


    KeyBanc turned bullish on The Trade Desk Inc. (TTD), upgrading the stock to “Overweight” and assigning an $851.0 price target, representing a potential upside of 30.09% from Friday’s close. 

    IQVIA Holdings Inc. (IQV) has won the favor of KeyBanc’s equity research team. The firm upgraded the shares from Sector Weight to Overweight and moved their price target to $218.0, suggesting a 15.61% additional upside for the stock. 

    The Coca-Cola Company (KO) received an upgrade from analysts at RBC Capital, who also set their one-year price target on the stock to $60.0. They changed their rating on KO to Outperform from Sector Perform in a recently issued research note. 

    Earlier Monday KeyBanc reduced its rating on PRA Health Sciences Inc. (PRAH) stock to Sector Weight from Overweight. 

    KeyBanc analysts reduced their investment ratings, saying in research reports covered by the media that its rating for Entergy Corporation (ETR) has been changed to Sector Weight from Overweight. 

    Analysts at Goldman Sachs downgraded Viatris Inc. (VTRS)’s stock to Neutral from Buy Monday.

    Latest Insider Activity


    Freeport-McMoRan Inc. (FCX) Director FORD GERALD J announced the sale of shares taking place on Mar 04 at $33.24 for some 300,000 shares. The total came to more than $9.97 million. 

    Zynga Inc. (ZNGA) Director DUGAN REGINA E sold on Mar 04 a total of 214,588 shares at $10.53 on average. The insider’s sale generated proceeds of almost $94244.0. 

    Cleveland-Cliffs Inc. (CLF) EVP, Chief Financial Officer Koci Keith declared the purchase of shares taking place on Mar 05 at $13.45 for some 15,000 shares. The transaction amount was around $0.2 million. 

    Enterprise Products Partners L.P. (EPD) Director WILLIAMS RANDA DUNCAN bought on Mar 04 a total of 4,915,183 shares at $22.90 on average. The purchase cost the insider an estimated $6.96 million.

    Important Earnings

    Top US earnings releases scheduled for today include Waitr Holdings Inc. (NASDAQ:WTRH). It will announce its Dec 2020 financial results. The company is expected to report earnings of $0.04 per share from revenues of $51.36M in the three-month period. 

    Analysts expect ContextLogic Inc. (NASDAQ:WISH) to report a net income (adjusted) of -$3.03 per share, when the company releases its quarterly results shortly. Revenue for the fiscal quarter ended Dec 2020 is predicted to come in at $736.11M. 

    CarParts.com Inc. (PRTS), due to announce earnings after the market closes today, is expected to report earnings of -$0.1 per share from revenues of $91.97M recently concluded three-month period.

  • 32 Stocks Making Sharp Moves in Pre Market Session

    32 Stocks Making Sharp Moves in Pre Market Session

    Sundial Growers Inc. (SNDL) stock soared 1.72% to $0.5088 in the pre-market trading after declaring $50 million prepayment on senior secured non-revolving term credit facility. The most recent rating by CIBC, on August 17, 2020, is a Neutral.

    FuelCell Energy Inc. (FCEL) is up more than 2.09% at $8.31 in pre-market hours Wednesday December 16, 2020. The stock had jumped over 5.71% to $8.14 in the last trading session.

    BioCardia Inc. (NASDAQ: BCDA) shares are trading up 5.22% at $7.05 at the time of writing after reporting that it has entered into definitive agreements with investors for the purchase and sale of 1,789,474 shares of its common stock at a purchase price of $4.75 per share Company’s 52-week ranged between $1.91 to $6.95.

    Before the trading started on December 16, 2020, MicroVision Inc. (MVIS) is down -1.9% to reach $4.13. It has been trading in a 52-week range of $0.15 to $3.45.

    Apartment Investment and Management Company (AIV) tumbled over -6.75% at $4.7 in pre-market trading today following completion of separation of Apartment Income REIT Corp.

    Before the trading started on December 16, 2020, GeoVax Labs Inc. (GOVX) is down -7.86% to reach $3.4. It has been trading in a 52-week range of $2.30 to $60.00.

    Anchiano Therapeutics Ltd. (ANCN), a Biotechnology company, dropped about -7.99% at $2.65 in pre-market trading Wednesday after the company and and Chemomab Ltd. declared their entry into a definitive merger agreement.

    BEST Inc. (NYSE: BEST) shares are trading up 3.29% at $2.2 at the time of writing. Company’s 52-week ranged between $2.36 to $6.54. Analysts have a consensus price target of $3.50.

    Veru Inc. (VERU) stock moved down -7.5 percent to $8.63 in the pre-market trading. The company lately reported positive Phase 2 clinical trial results for Enobosarm.

    Northern Dynasty Minerals Ltd. (NAK) is up more than 3.67% at $0.325 in pre-market hours Wednesday December 16, 2020. The stock had dropped over -4.74% to $0.31 in the last trading session.

    Moderna Inc. (MRNA) stock plunged -3.33% to $142.32 in the pre-market trading. The company recently confirmed supply agreement with the Ministry of Health to supply Singapore with mRNA vaccine against COVID-19 (mRNA-1273). The most recent rating by Needham, on December 09, 2020, is a Hold.

    Before the trading started on December 16, 2020, Teligent Inc. (TLGT) is up 2.2% to reach $0.93. It has been trading in a 52-week range of $0.46 to $6.46.

    HEXO Corp. (HEXO), a Drug Manufacturers – Specialty & Generic company, rose about 2.75% at $1.12 in pre-market trading Wednesday. The firm recently revealed it first quarter fiscal 2021 financial results.

    Gevo Inc. (NASDAQ: GEVO) shares are trading up 4.74% at $1.99 at the time of writing. Company’s 52-week ranged between $0.46 to $2.91.

    Timber Pharmaceuticals Inc. (TMBR) stock moved down -0.97 percent to $1.02 in the pre-market trading after receiving notice of allowance from U.S. Patent and Trademark Office for Lead Asset TMB-001.

    Baidu Inc. (BIDU) is up more than 4.33% at $193.53 in pre-market hours Wednesday December 16, 2020. The stock had jumped over 13.83% to $185.50 in the last trading session.

    Aurora Cannabis Inc. (ACB) gained over 1.76% at $10.39 in pre-market trading Wednesday December 16, 2020 after provided a business update.

    Velodyne Lidar Inc. (VLDR) stock soared 3.91% to $20.2 in the pre-market trading after declaring a sales agreement for Alpha Prime sensors with May Mobility, a pioneer in autonomous vehicle (AV) technology. The most recent rating by Needham, on December 15, 2020, is a Buy.

    Before the trading started on December 16, 2020, Nikola Corporation (NKLA) is up 3.64% to reach $17.08. It has been trading in a 52-week range of $10.29 to $93.99.

    PG&E Corporation (NYSE: PCG) shares are trading up 2.87% at $12.55 at the time of writing after paying over $268 million in property taxes to 50 California counties. Company’s 52-week ranged between $6.25 to $18.34. Analysts have a consensus price target of $15.

    SELLAS Life Sciences Group Inc. (SLS) tumbled over -3.72% at $6.99 in pre-market trading today. The firm recently reported the pricing of $16.2 million registered direct offering.

    Nxt-ID Inc. (NASDAQ: NXTD) shares are trading down -1.66% at $0.4795 at the time of writing. Company’s 52-week ranged between $0.21 to $0.89.

    Qualigen Therapeutics Inc. (QLGN), a Biotechnology company, rose about 1.23% at $4.12 in pre-market trading Wednesday following its announcement of issuance of U.S. Patent for expanded applications of ALAN Anticancer Platform Technology.

    Concord Medical Services Holdings Limited (CCM) lost over -30.32% at $3.7 in pre-market trading Wednesday December 16, 2020.

    Aphria Inc. (APHA) grew over 11.45% at $9.05 in pre-market trading today following its declaration of definitive agreement with Tilray, Inc. (TLRY), to combine their businesses and create the world’s largest global cannabis company.

    Before the trading started on December 16, 2020, Hecla Mining Company (HL) is up 5.9% to reach $5.74. It has been trading in a 52-week range of $1.40 to $6.79.

    Twitter Inc. (TWTR), a Internet Content & Information company, rose about 3.1% at $54.46 in pre-market trading Wednesday after the declaration from the Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (AMZN), that Twitter (TWTR) has selected AWS to provide global cloud infrastructure to deliver Twitter timelines.

    Torchlight Energy Resources Inc. (TRCH) stock plunged -4.63% to $0.5332 in the pre-market trading. The most recent rating by ROTH Capital, on March 13, 2020, is a Neutral.

    Arvinas Inc. (ARVN) is up more than 1.41% at $75.3 in pre-market hours Wednesday December 16, 2020 after reporting the pricing of an underwritten public offering of 5,714,286 shares of its common stock at a price of $70.00 per share, before underwriting discounts and commissions.

    Cinedigm Corp. (CIDM) stock plunged -0.54% to $0.84 in the pre-market trading. The most recent rating by The Benchmark Company, on July 07, 2020, is a Speculative buy.

    PDL BioPharma Inc. (PDLI) grew over 6.59% at $2.75 in pre-market trading today. The company recently reported that it has entered into a Capital Provision Agreement with Epps Investments LLC.

    vTv Therapeutics Inc. (VTVT) is down more than -31.99% at $2.02 in pre-market hours Wednesday December 16, 2020 after revealing that the Phase 2 Elevage study of azeliragon in people with mild Alzheimer’s disease and type 2 diabetes did not meet its primary objective of demonstrating an improvement in cognition as assessed by the 14-item Alzheimer’s Disease Assessment Scale – Cognitive Subscale (ADAS-cog14) relative to placebo.